Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Lakewood, California Clinical Trials

A listing of Lakewood, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (5) clinical trials

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular Age-related Macular Degeneration (PANDA-1)

A multicenter, multinational, double-masked, parallel-group, dose-ranging, active-controlled, randomized trial, which will randomize approximately 1140 subjects in a ratio of 1:1:1 to receive IVT injections of 0.5 mg conbercept, 1.0 mg conbercept, or 2.0 mg aflibercept. The trial includes a screening period of less than or equal to 14 days, followed ...

Phase

3.11 miles

Learn More »

A Phase 2 Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia

This is a Phase 2, randomized, double-blinded, placebo-controlled, inpatient study to examine the efficacy, safety, and tolerability profile of KarXT in adult subjects diagnosed with DSM-5 schizophrenia who are in an acute exacerbation phase. The primary objective of the study is to assess the efficacy of KarXT (a fixed combination ...

Phase

4.58 miles

Learn More »

The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine

This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the potential for clinical dependence and withdrawal symptoms associated with valbenazine.

Phase

4.67 miles

Learn More »

Brief Intervention by Community Health Workers for Unhealthy Drinking in Latinos

Latinos will comprise nearly 30% of the population by 2050, and socially disadvantaged Latinos experience a greater burden of poor health and negative social consequences related to their alcohol use than non-Latino Whites. The burden of poor health related to alcohol use also suggests the need for early identification and ...

Phase N/A

8.85 miles

Learn More »

A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome

An Open Label, Intra-Subject Dose Escalation Study of CCX140 B in Subjects with Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome. The aim of this study is to explore the effect of CCX140-B, a selective antagonist of C-C chemokine receptor type 2, on proteinuria in subjects with FSGS.

Phase

9.23 miles

Learn More »